Hypertension - Pipeline Review, H2 2019
Hypertension - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2019, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 2, 37, 40, 27, 1, 80, 24 and 5 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 8 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2019, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 2, 37, 40, 27, 1, 80, 24 and 5 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 8 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hypertension - Overview
Hypertension - Therapeutics Development
Hypertension - Therapeutics Assessment
Hypertension - Companies Involved in Therapeutics Development
Hypertension - Drug Profiles
Hypertension - Dormant Projects
Hypertension - Discontinued Products
Hypertension - Product Development Milestones
Appendix
Hypertension - Overview
Hypertension - Therapeutics Development
Hypertension - Therapeutics Assessment
Hypertension - Companies Involved in Therapeutics Development
Hypertension - Drug Profiles
Hypertension - Dormant Projects
Hypertension - Discontinued Products
Hypertension - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypertension - Pipeline by A1M Pharma AB, H2 2019
Hypertension - Pipeline by Aadi Bioscience Inc, H2 2019
Hypertension - Pipeline by Abivax SA, H2 2019
Hypertension - Pipeline by Acceleron Pharma Inc, H2 2019
Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2019
Hypertension - Pipeline by Adhera Therapeutics, H2 2019
Hypertension - Pipeline by Aerogen Ltd, H2 2019
Hypertension - Pipeline by Aggamin LLC, H2 2019
Hypertension - Pipeline by AI Therapeutics, H2 2019
Hypertension - Pipeline by Ajanta Pharma Ltd, H2 2019
Number of Products under Development for Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Universities/Institutes, H2 2019
Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hypertension - Pipeline by A1M Pharma AB, H2 2019
Hypertension - Pipeline by Aadi Bioscience Inc, H2 2019
Hypertension - Pipeline by Abivax SA, H2 2019
Hypertension - Pipeline by Acceleron Pharma Inc, H2 2019
Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2 2019
Hypertension - Pipeline by Adhera Therapeutics, H2 2019
Hypertension - Pipeline by Aerogen Ltd, H2 2019
Hypertension - Pipeline by Aggamin LLC, H2 2019
Hypertension - Pipeline by AI Therapeutics, H2 2019
Hypertension - Pipeline by Ajanta Pharma Ltd, H2 2019
LIST OF FIGURES
Number of Products under Development for Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
A1M Pharma AB
Aadi Bioscience Inc
Abivax SA
Acceleron Pharma Inc
Actelion Pharmaceuticals Ltd
Adhera Therapeutics
Aerogen Ltd
Aggamin LLC
AI Therapeutics
Ajanta Pharma Ltd
Alnylam Pharmaceuticals Inc
Altavant Sciences Inc
AMAG Pharmaceuticals Inc
AnGes Inc
AOBiome LLC
Apaxen
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
Attgeno AB
ATXA Therapeutics Ltd
AVEO Oncology Inc
Bayer AG
Beijing Wehand-Bio Pharmaceutical Co Ltd
Bial - Portela & Ca SA
Biogen Inc
BioRestorative Therapies Inc
BioStem Technologies Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
CardioPharma Inc
Cellmid Ltd
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
CinCor Pharma Inc
CJ HealthCare Corp
Complexa Inc
CSPC Pharmaceutical Group Ltd
Cumberland Pharmaceuticals Inc
D. Western Therapeutics Institute Inc
Daewon Pharmaceutical Co Ltd
Daewoong Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Eldrug SA
Eli Lilly and Co
Elyson Pharmaceutical Co Ltd
Esperion Therapeutics Inc
Excubio Pharmaceuticals Inc
FunPep Co Ltd
Galectin Therapeutics Inc
Gemphire Therapeutics Inc
GenKyoTex SA
GenThera Inc
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm Ltd
Gossamer Bio Inc
Guangzhou Magpie Pharmaceutical Co Ltd
H. Lundbeck AS
Hanmi Pharmaceuticals Co Ltd
Hetero Labs Ltd
Himuka AM Pharma Corp
Idorsia Pharmaceutical Ltd
Innolife Co Ltd
Innopharmax Inc
Insmed Inc
Insys Therapeutics Inc
Inven2 AS
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
KBP BioSciences Co Ltd
Kyowa Kirin Co Ltd
Kyung Dong Co Ltd
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
LG Chem Ltd
Liaoning Haiwang Biotechnoloty Co Ltd
LinXis BV
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Martin Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Mifcare
Morphogen-IX Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Noorik Biopharmaceuticals AG
Northern Therapeutics Inc
Novartis AG
NuSirt Biopharma Inc
Omeros Corp
Orion Corp
Overseas Pharmaceuticals Ltd
Panorama Research Inc
Park Active Molecules
Pharming Group NV
Pharmosa Biopharm Inc
PhaseBio Pharmaceuticals Inc
Proteo Inc
Pulmokine Inc
Q BioMed Inc
QR Pharmaceuticals Ltd
Quantum Genomics SA
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
Relypsa Inc
Renova Therapeutics Inc
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ridge Therapeutics LLC
RMJ Holdings LLC
Samik Pharmaceutical Co Ltd
Sanofi
Sarfez Pharmaceuticals Inc
Schrodinger LLC
Scipharm SaRL
Scohia Pharma Inc
Shanghai Pharmaceutical Co Ltd
Shanghai Xinyi Pharmaceutical Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
SJT Molecular Research SL
Sorrento Therapeutics Inc
Sosei Heptares
SteadyMed Therapeutics Inc
Stocosil Inc
Suda Pharmaceuticals Ltd
Sulfateq BV
Sun Pharma Advanced Research Company Ltd
Synokem Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Target Medicals LLC
Theracos Inc
Theragene Pharmaceuticals Inc
Theravance Biopharma Inc
Topadur Pharma AG
Translate Bio Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
VasThera Research Institute
Vectus Biosystems Ltd
Velocity Pharmaceutical Development LLC
VG Life Sciences Inc
Vivus Inc
Windtree Therapeutics Inc
XuanZhu Pharma Co Ltd
Yuhan Corp
Zhejiang Conba Pharmaceutical Co Ltd
Number of Products under Development for Hypertension, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
A1M Pharma AB
Aadi Bioscience Inc
Abivax SA
Acceleron Pharma Inc
Actelion Pharmaceuticals Ltd
Adhera Therapeutics
Aerogen Ltd
Aggamin LLC
AI Therapeutics
Ajanta Pharma Ltd
Alnylam Pharmaceuticals Inc
Altavant Sciences Inc
AMAG Pharmaceuticals Inc
AnGes Inc
AOBiome LLC
Apaxen
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
Attgeno AB
ATXA Therapeutics Ltd
AVEO Oncology Inc
Bayer AG
Beijing Wehand-Bio Pharmaceutical Co Ltd
Bial - Portela & Ca SA
Biogen Inc
BioRestorative Therapies Inc
BioStem Technologies Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
CardioPharma Inc
Cellmid Ltd
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
CinCor Pharma Inc
CJ HealthCare Corp
Complexa Inc
CSPC Pharmaceutical Group Ltd
Cumberland Pharmaceuticals Inc
D. Western Therapeutics Institute Inc
Daewon Pharmaceutical Co Ltd
Daewoong Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Eldrug SA
Eli Lilly and Co
Elyson Pharmaceutical Co Ltd
Esperion Therapeutics Inc
Excubio Pharmaceuticals Inc
FunPep Co Ltd
Galectin Therapeutics Inc
Gemphire Therapeutics Inc
GenKyoTex SA
GenThera Inc
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm Ltd
Gossamer Bio Inc
Guangzhou Magpie Pharmaceutical Co Ltd
H. Lundbeck AS
Hanmi Pharmaceuticals Co Ltd
Hetero Labs Ltd
Himuka AM Pharma Corp
Idorsia Pharmaceutical Ltd
Innolife Co Ltd
Innopharmax Inc
Insmed Inc
Insys Therapeutics Inc
Inven2 AS
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
KBP BioSciences Co Ltd
Kyowa Kirin Co Ltd
Kyung Dong Co Ltd
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
LG Chem Ltd
Liaoning Haiwang Biotechnoloty Co Ltd
LinXis BV
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Martin Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Mifcare
Morphogen-IX Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Noorik Biopharmaceuticals AG
Northern Therapeutics Inc
Novartis AG
NuSirt Biopharma Inc
Omeros Corp
Orion Corp
Overseas Pharmaceuticals Ltd
Panorama Research Inc
Park Active Molecules
Pharming Group NV
Pharmosa Biopharm Inc
PhaseBio Pharmaceuticals Inc
Proteo Inc
Pulmokine Inc
Q BioMed Inc
QR Pharmaceuticals Ltd
Quantum Genomics SA
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
Relypsa Inc
Renova Therapeutics Inc
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ridge Therapeutics LLC
RMJ Holdings LLC
Samik Pharmaceutical Co Ltd
Sanofi
Sarfez Pharmaceuticals Inc
Schrodinger LLC
Scipharm SaRL
Scohia Pharma Inc
Shanghai Pharmaceutical Co Ltd
Shanghai Xinyi Pharmaceutical Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
SJT Molecular Research SL
Sorrento Therapeutics Inc
Sosei Heptares
SteadyMed Therapeutics Inc
Stocosil Inc
Suda Pharmaceuticals Ltd
Sulfateq BV
Sun Pharma Advanced Research Company Ltd
Synokem Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Target Medicals LLC
Theracos Inc
Theragene Pharmaceuticals Inc
Theravance Biopharma Inc
Topadur Pharma AG
Translate Bio Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
VasThera Research Institute
Vectus Biosystems Ltd
Velocity Pharmaceutical Development LLC
VG Life Sciences Inc
Vivus Inc
Windtree Therapeutics Inc
XuanZhu Pharma Co Ltd
Yuhan Corp
Zhejiang Conba Pharmaceutical Co Ltd
